Anti-FASN (Fatty Acid Synthase)

Fatty Acid Synthase (FASN) catalyzes the synthesis of palmitate from acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids. In some cancer, cell lines, this protein has been found to be fused with estrogen receptor-alpha (ER-alpha), in which the N-terminus of FASN is fused in-frame with the C-terminus of ER-alpha. FASN is, highly expressed in adipocytes and liver. FASN is a central enzyme in de novo lipogenesis. FASN is a target for SREBP and is upregulated by LXR activation, it is also one of the accepted markers for insulin resistance, SREBP and LXR activation. FASN: Bovine: 2513 aa, Pig: 2411 aa, Chick: 2511 aa, Mouse: 2504 aa, Rat: 2505 aa, Human: 2511 aa, 273.4kD, 17q25. Expression: Ubiquitous, more prominent expression in brain, lungs, and liver. Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 1-10mg/ml chemiluminescence technique., Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.